Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PRS-344/S095012 · 1 trial · 1 indication
Phase 1: Incidence of dose-limiting toxicities (DLTs) over the first 28-days of study treatment
Phase 2: Defined as Complete Response (CR) plus Partial Response (PR). For arms 1 and 2, per central assessment according to RECIST v1.1 criteria. For Arm 3, per central assessment and composite response criteria (digital medical photography and/or imaging as per RECIST v1.1)
| Arm | Type | Description |
|---|---|---|
| PRS-344/S095012 | EXPERIMENTAL | PRS-344/S095012 |
| Name | Type | Description |
|---|---|---|
| PRS-344/S095012 | DRUG | PRS-344/S095012 Monotherapy |
Inclusion Criteria: 1. Age ≥18 years on the day the consent is signed. 2. Patients with histologically confirmed diagnosis of unresectable, locally advanced or metastatic solid tumor for which standard treatment options are not available, no longer effective, or not tolerated. 3. Patient should hav...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
PRS-344/S095012 is an investigational small molecule being developed for the treatment of solid tumors. It is currently in Phase 1 clinical development and has been studied in a completed trial involving patients with solid tumors.
PRS-344/S095012 is a PD-L1x4-1BB bispecific antibody-Anticalin fusion protein. It targets PD-L1 and 4-1BB, which are proteins involved in immune regulation. The drug is designed to modulate these targets to potentially treat solid tumors.
PRS-344/S095012 is being developed by Tango Therapeutics, Inc., a biopharmaceutical company. The company's stock is traded under the ticker symbol TNGX.
PRS-344/S095012 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. A Phase 1 trial has been completed to evaluate its safety and efficacy in patients with solid tumors.
PRS-344/S095012 has been studied in a Phase 1 clinical trial with the identifier NCT05159388. This trial, titled 'A Study of PRS-344/S095012 (PD-L1x4-1BB Bispecific Antibody-Anticalin Fusion) in Patients With Solid Tumors,' enrolled 45 participants and has been completed. The trial was conducted in the United States, Australia, Belgium, and Spain.
Yes, PRS-344/S095012 is also known as S095012. The drug is a PD-L1x4-1BB bispecific antibody-Anticalin fusion protein being developed for solid tumors. It is currently in Phase 1 clinical development.